Mazdutide Overview
Mechanism of Action
Mazdutide is a dual GLP-1 and glucagon receptor agonist. It combines GLP-1-mediated appetite suppression with glucagon-driven energy expenditure increases and hepatic fat oxidation. The glucagon component specifically targets liver fat reduction.
~7 days
Timing
Same day each week
Injection Site
Subcutaneous
Food
No restrictions
Common Stacks
- Lifestyle modification
- B12 supplementation
Mazdutide Dosing Protocol
Initiation
4 weeks1 mg weekly
Starting dose.
Titration
4 weeks per stepIncrease 1–3 mg monthly
Titrate to tolerance.
Maintenance
Ongoing6–9 mg weekly
Target maintenance.
Mazdutide Expected Timeline
Week 1–4
Appetite suppression; GI adaptation
Month 1–3
Progressive weight loss
Month 3–6
Significant weight reduction
Mazdutide Side Effects
Nausea
Diarrhea
Decreased appetite
Injection site reactions
Mazdutide Research Studies
Mazdutide for type 2 diabetes and obesity (GLORY-2)
Ji L, et al. — Lancet Diabetes Endocrinol (2024)
Phase 3: mazdutide 9 mg produced significant weight loss and HbA1c reduction, confirming dual GLP-1/glucagon mechanism.
PubMed: 38531367Mazdutide FAQ
How does mazdutide compare to semaglutide?
Mazdutide adds glucagon receptor activation, increasing energy expenditure and liver fat oxidation beyond GLP-1-only drugs.
Is mazdutide the same as retatrutide?
No. Mazdutide is dual (GLP-1 + glucagon). Retatrutide is triple (GLP-1 + GIP + glucagon). Retatrutide adds GIP for insulin sensitivity.